Synergic effect of simvastatin in combination with amphotericin B against environmental strains of Cryptococcus neoformans from northeastern Brazil
a prospective experimental study
Keywords:
Cryptococcosis, Cryptococcus neoformans, Drug resistance, fungal, Antifungal agents, Drug interactionsAbstract
BACKGROUND: Statins are used as cholesterol-lowering drugs and may also have direct antimicrobial effects. OBJECTIVE: To evaluate synergic interactions between simvastatin and both amphotericin B and fluconazole, against environmental strains of Cryptococcus neoformans isolated from captive birds’ droppings.DESIGN AND SETTING: Experimental study conducted at Federal University of Piauí, Parnaíba, in collaboration with Federal University of Triângulo Mineiro, Uberaba, Brazil. METHODS: Statin susceptibility tests of Cryptococcus neoformans samples were performed as prescribed in standards. Interactions of simvastatin with amphotericin and fluconazole were evaluated using the checkerboard microdilution method. Presence of these interactions was quantitatively detected through determining the fractional inhibitory concentration index (FICI). RESULTS: Isolates of Cryptococcus neoformans were obtained from 30 of the 206 samples of dry bird excreta (14.5%) that were collected from pet shops and houses. Ten isolates were selected for susceptibility tests. All of them were susceptible to amphotericin and fluconazole. All presented minimum inhibitory concentration (MIC) > 128 µg/ml and, thus, were resistant in vitro to simvastatin. An in vitro synergic effect was shown through combined testing of amphotericin B and simvastatin, such that six isolates (60%) presented FICI < 0.500. Two isolates showed considerable reductions in MIC, from 1 µg/ml to 0.250 µg/ml. No synergic effect was observed through combining fluconazole and simvastatin. CONCLUSION: These results demonstrate that simvastatin should be considered to be a therapeutic alternative, capable of potentiating the action of amphotericin B. However, further studies are necessary to clarify the real effect of simvastatin as an antifungal agent.
Downloads
References
Archibald LK, Tuohy MJ, Wilson DA, et al. Antifungal susceptibilities of Cryptococcus neoformans Emerg Infect Dis. 2004;10(1):143-5. PMID: 15078612; doi: 10.3201/eid1001.020779.
Park YD, Sun W, Salas A, et al. Identification of multiple cryptococcal fungicidal drug targets by combined gene dosing and drug affinity responsive target stability screening. MBio. 2016;7(4). pii: e01073-16. PMID: 27486194; doi: 10.1128/mBio.01073-16.
Tewari A, Behera B, Mathur P, Xess I. Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans Mycopathologia. 2012;173(5-6):427-33. PMID: 22354778; doi: 10.1007/s11046-012-9528-9.
Chandenier K, Adou-Bryn KD, Douchet C, et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis. 2004;23(6):506-8. PMID: 15141336; doi: 10.1007/s10096-004-1136-2.
Almeida AM, Matsumoto MT, Baeza LC, et al. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from São Paulo State, Brazil. FEMS Yeast Res. 2007;7(1):152-64. PMID: 17311593; doi: 10.1111/j.1567-1364.2006.00128.x.
Ferreira-Paim K, Andrade-Silva L, Mora DJ, et al. Antifungal susceptibility, enzymatic activity, PCR fingerprinting and ITS sequencing of environmental Cryptococcus laurentii isolates from Uberaba, Minas Gerais, Brazil. Mycopathologia. 2012;174(1):41-52. PMID: 22116628; doi: 10.1007/s11046-011-9500-0.8.
Scorzoni L, Paula e Silva ACA, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol. 2015;8(36):1-23. PMID: 28167935; doi: 10.3389/fmicb.2017.00036.
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Ver Pharmacol. 2005;45:89-118. PMID: 15822172; doi: 10.1146/annurev.pharmtox.45.120403.095748.
Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans Antimicrob Agents Chemother. 1997;41(4):850-2. PMID: 9087504.
Brilhante RS, Caetano EP, Oliveira JS, et al. Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species Braz J Infect Dis. 2015;19(5):459-65. PMID: 26119850; doi: 10.1016/j.bjid.2015.06.001.
Randhawa HS, Kowshik T, Khan ZU. Efficacy of swabbing versus a conventional technique for isolation of Cryptococcus neoformans from decayed wood in tree trunk hollows. Med Mycol. 2005;43(1):67-71. PMID: 15712609.
Bolano A, Stinchi S, Preziosi R, et al. Rapid methods to extract DNA and RNA from Cryptococcus neoformans FEMS Yeast Res. 2001;1(3): 221-4. PMID: 12702347; doi: 10.1111/j.1567-1364.2001.tb00037.x.
Meyer W, Castaneda A, Jackson S, et al. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003;9(2):189-95. PMID: 12603989; doi: 10.3201/eid0902.020246.
Clinical Laboratory Standard Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standards-Third edition. 2008;28(14):M27-A3. ISBN: 1-56238-666-2.
Souza LK, Fernandes Ode F, Kobayashi CC, et al. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city, Goias, Brazil. Rev Inst Med Trop Sao Paulo. 2005;47(5):253-6. PMID: 16302107; doi: 10.1590/S0036-46652005000500003.
Leão CA, Ferreira-Paim K, Andrade-Silva L, et al. Primary cutaneous cryptococcosis caused by Cryptococcus gattii in an immunocompetent host. Med Mycol. 2011;49(4):352-5. PMID: 21028946; doi: 10.3109/13693786.2010.530697.
Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they? J Antimicrob Chemother. 2004;54(5):854-869. PMID: 15375111; doi: 10.1093/jac/dkh434.
Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. PMID: 12805255; doi: 10.1093/jac/dkg301.
Ferreira-Paim K, Andrade-Silva L, Mora DJ, et al. Genotyping of Cryptococcus neoformans isolated from captive birds in Uberaba, Minas Gerais, Brazil. Mycoses. 2010;54(5):e294-300. PMID: 20492533; doi: 10.1111/j.1439-0507.2010.01901.x.
Costa AK, Sidrim JJ, Cordeiro RA, et al. Urban pigeons (Columba livia) as a potential source of pathogenic yeasts: a focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. Mycopathologia. 2010;169(3):207-13. PMID: 19847668; doi: 10.1007/s11046-009-9245-1.
Lugarini C, Condas LAZ, Soresini GCG, et al. Screening of antigenemia and isolation of Cryptococcus neoformans and Cryptococcus gattii from cloaca and crop of birds in the state of Paraná, Brazil. Pesqu Vet Bras. 2008;28(7):341-4. doi: 10.1590/S0100-736X2008000700004.
Casali AK, Goulart L, Rosa e Silva LK, et al. Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res. 2003;3(4):405-15. PMID: 12748052; doi: 10.1016/S1567-1356(03)00038-2.
Cogliati M, D’Amicis R, Zani A, et al. Environmental distribution of Cryptococcus neoformans and C. gattii around the Mediterranean basin. FEMS Yeast Res. 2016;16(4). pii: fow045. PMID: 27188887; doi: 10.1093/femsyr/fow045.
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol. 2005;43(8):3807-10. PMID: 16081915; doi: 10.1128/JCM.43.8.3807-3810.2005.
Galgóczy L, Papp T, Kovács L, Ordögh L, Vágvölgyi C. In vitro activity of phenothiazines and their combinations with amphotericin B against Zygomycetes causing rhinocerebral zygomycosis. Med Mycol. 2009;47(3):331-5. PMID: 18798117; doi: 10.1080/13693780802378853.
Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother. 2008;61(4):774-85. PMID: 18263570; doi: 10.1093/jac/dkn019.
Sun HY, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid organ transplant recipients. Clin Infect Dis. 2009;48(6):745-55. PMID: 19193110; doi: 10.1086/597039.
Nyilasi I, Kocsubé S, Krizsán K, et al. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol Lett. 2010;307(2):175-84. PMID: 20636975; doi: 10.1111/j.1574-6968.2010.01972.x.
